StatisticsWe have 222 registered users
The newest registered user is raheelmemon
Our users have posted a total of 1140 messages in 613 subjects
If you are seeing this, you have attempted to link to the UpToDate widget but are experiencing a problem. Please visit UpToDate for more information.
Page 1 of 1 • Share •
Quantifying the Benefits and Risks of Methylphenidate
as Treatment for Childhood ADHD
JAMA published this article on May 10, 2016 (JAMA. 2016;315(18):1953-1955) which summarizes Cochrane review (BMJ. 2015;351:h5203) to evaluate the benefits and risks of methylphenidate (MPH) as treatment for childhood ADHD.
* Based on rating by teachers: MPH associated with improvement of core symptoms of ADHD and general behavior problems.
* Based on clinical impression by parents: MPH associated with parent's clinical impression of improved child's quality of life.
* Methylphenidate associated with non serious side effects- decreased appetite and Insomnia.
* This increase not found for serious adverse events.
* Authors reports that all of 185 included trials were flawed- high risk of bias. Authors questioned the therapeutic benefit of MPH and do not support the inclusion of MPH in treatment guidelines for ADHD.
Sources of Bias considered by authors:
* How randomization was conducted
* Concealment of allocation
* Participants and personnel blinding
* Outcome assessment bliniding
* Incomplete outcome date
* Selective reporting
* Vested interest bias
Click on to post your comments
Page 1 of 1
Permissions in this forum:You cannot reply to topics in this forum